Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: FSD2

Gene summary for FSD2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

FSD2

Gene ID

123722

Gene namefibronectin type III and SPRY domain containing 2
Gene AliasSPRYD1
Cytomap15q25.2
Gene Typeprotein-coding
GO ID

GO:0005575

UniProtAcc

A1L4K1


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
123722FSD2HCC1HumanLiverHCC6.31e-221.60e+000.5336
123722FSD2HCC2HumanLiverHCC6.04e-302.02e+000.5341
123722FSD2HCC5HumanLiverHCC4.49e-231.51e+000.4932
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00066505EsophagusESCCglycerophospholipid metabolic process174/8552306/187234.92e-053.85e-04174
GO:00065757EsophagusESCCcellular modified amino acid metabolic process112/8552188/187238.31e-056.06e-04112
GO:003030710EsophagusESCCpositive regulation of cell growth100/8552166/187231.07e-047.55e-04100
GO:00066358EsophagusESCCfatty acid beta-oxidation50/855274/187231.16e-048.04e-0450
GO:001097516EsophagusESCCregulation of neuron projection development240/8552445/187232.48e-041.53e-03240
GO:00620129EsophagusESCCregulation of small molecule metabolic process184/8552334/187233.11e-041.85e-03184
GO:00352647EsophagusESCCmulticellular organism growth80/8552132/187233.84e-042.22e-0380
GO:00723297EsophagusESCCmonocarboxylic acid catabolic process74/8552122/187236.03e-043.27e-0374
GO:00464864EsophagusESCCglycerolipid metabolic process211/8552392/187236.51e-043.46e-03211
GO:00421805EsophagusESCCcellular ketone metabolic process120/8552211/187236.70e-043.55e-03120
GO:00442427EsophagusESCCcellular lipid catabolic process121/8552214/187238.63e-044.43e-03121
GO:00450568EsophagusESCCtranscytosis17/855221/187231.03e-035.19e-0317
GO:00442827EsophagusESCCsmall molecule catabolic process201/8552376/187231.35e-036.41e-03201
GO:00302586EsophagusESCClipid modification116/8552212/187234.90e-031.89e-02116
GO:01501724EsophagusESCCregulation of phosphatidylcholine metabolic process9/855210/187235.09e-031.92e-029
GO:003563310EsophagusESCCmaintenance of blood-brain barrier24/855235/187235.25e-031.97e-0224
GO:00215436EsophagusESCCpallium development94/8552169/187235.79e-032.14e-0294
GO:00160427EsophagusESCClipid catabolic process168/8552320/187237.97e-032.84e-02168
GO:001635816EsophagusESCCdendrite development130/8552243/187238.33e-032.95e-02130
GO:004592717EsophagusESCCpositive regulation of growth137/8552259/187231.13e-023.80e-02137
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
FSD2SNVMissense_Mutationrs200109394c.1411N>Tp.Pro471Serp.P471SA1L4K1protein_codingdeleterious(0.04)probably_damaging(1)TCGA-A7-A26E-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapycytoxanSD
FSD2SNVMissense_Mutationc.413N>Tp.Gly138Valp.G138VA1L4K1protein_codingdeleterious(0.04)benign(0.348)TCGA-AN-A0AM-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationrs774888742c.1499N>Tp.Ser500Leup.S500LA1L4K1protein_codingdeleterious(0)probably_damaging(0.998)TCGA-D8-A142-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycyclophosphamidSD
FSD2SNVMissense_Mutationc.923C>Ap.Thr308Lysp.T308KA1L4K1protein_codingdeleterious(0.01)benign(0.435)TCGA-D8-A1X9-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapyadriamycin+cyclophosphamideSD
FSD2SNVMissense_Mutationrs781225191c.388G>Ap.Glu130Lysp.E130KA1L4K1protein_codingtolerated(0.07)benign(0.096)TCGA-DS-A0VK-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycarboplatinPD
FSD2SNVMissense_Mutationnovelc.493N>Tp.Val165Phep.V165FA1L4K1protein_codingdeleterious(0)probably_damaging(0.957)TCGA-DS-A1OC-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapygemcitabineSD
FSD2SNVMissense_Mutationc.520N>Ap.Glu174Lysp.E174KA1L4K1protein_codingtolerated(0.07)possibly_damaging(0.867)TCGA-JW-A5VL-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationc.1398G>Ap.Met466Ilep.M466IA1L4K1protein_codingtolerated(0.05)benign(0.003)TCGA-LP-A4AV-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
FSD2SNVMissense_Mutationc.88G>Ap.Glu30Lysp.E30KA1L4K1protein_codingtolerated(0.41)benign(0.006)TCGA-VS-A8QC-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapypaclitaxelPD
FSD2SNVMissense_Mutationnovelc.586N>Ap.Glu196Lysp.E196KA1L4K1protein_codingdeleterious(0.04)benign(0.157)TCGA-ZJ-AAXU-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 7 8 9 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1